Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Doxazosin Attenuates Development of Testosterone Propionate-induced Prostate Growth by regulating TGF-β/Smad Signaling Pathway, Prostate-specific Antigen Expression and Reversing Epithelial-mesenchymal Transition in Mice and Stroma Cells.
Curr Mol Pharmacol
January 2025
School of Medicine, Yichun University, 576 XueFu Road, Yuanzhou District, Yichun 336000, Jiangxi Province, China.
Background: Finasteride and doxazosin are used for the treatment of benign prostatic hyperplasia (BPH) and lower urinary tract symptoms (LUTS). Epithelial-mesenchymal transition (EMT) plays an important role in BPH, little is known about the growth inhibition and anti-fibrosis effects of doxazosin on the regulation of EMT and morphology in the prostate.
Objectives: The present study examined the effects of doxazosin on testosterone propionate (TP)-induced prostate growth in vivo and in vitro and its impact on the EMT and TGF-β/Smad signaling pathway.
Change in prostate tissue gene expression following finasteride or doxazosin administration in the medical therapy for prostatic symptoms (MTOPS) study.
Sci Rep
August 2024
Department of Preventive Medicine, College of Medicine, University of Tennessee Health Science Center, Memphis, TN, 38163, USA.
Benign prostatic hyperplasia (BPH) may decrease patient quality of life and often leads to acute urinary retention and surgical intervention. While effective treatments are available, many BPH patients do not respond or develop resistance to treatment. To understand molecular determinants of clinical symptom persistence after initiating BPH treatment, we investigated gene expression profiles before and after treatments in the prostate transitional zone of 108 participants in the Medical Therapy of Prostatic Symptoms (MTOPS) Trial.
View Article and Find Full Text PDFREVIEW OF ADVERSE DRUG REACTIONS OF MEDICINES USED FOR THE TREATMENT OF BENIGN PROSTATIC HYPERPLASIA REPORTED TO HALMED.
Acta Clin Croat
July 2023
Agency for Medicinal Products and Medical Devices of Croatia (HALMED), Zagreb, Croatia.
Benign prostatic hyperplasia is one of the most common diseases in men, with a prevalence rate of 50% in their 50s to 80% in their 80s, and is mostly treated with chronic drug therapy. The aim of this study was to analyze adverse drug reactions (ADR) to drugs used in benign prostate hyperplasia (BPH) treatment reported to HALMED from 2008 to 2021. Data on ADR reports in Croatia were obtained from the VigiFlow national database and on the use of drugs for BPH in Croatia from Drug Utilization Reports from HALMED.
View Article and Find Full Text PDFThe Reduction of Male Lower Urinary Tract Symptoms Is Associated With a Decreased Risk of Death.
J Urol
October 2023
London Health Sciences Center, London, Ontario, Canada.
Purpose: Male lower urinary tract symptoms have been correlated with an increased risk of death; however, it is unclear if treatment will reduce this risk. Our objective was to determine whether a reduction in lower urinary tract symptoms is associated with a reduced risk of mortality.
Materials And Methods: We conducted a secondary analysis of the MTOPS (Medical Treatment of Prostate Symptoms) randomized trial of placebo, doxazosin, finasteride, or doxazosin and finasteride.
Development of a machine learning-based predictive model for prediction of success or failure of medical management for benign prostatic hyperplasia.
Neurourol Urodyn
April 2023
Urology Institute, University Hospitals Cleveland Medical Center, Cleveland, Ohio, USA.
Article Synopsis
- The study aimed to create a predictive model to identify BPH patients likely to respond to medical treatment and those who won't.
- Researchers analyzed data from 2,172 BPH patients treated with three different therapies, employing machine learning techniques to select the most effective model.
- The final boosted support vector machine model achieved an overall accuracy (AUC) of 0.698, indicating a reasonable ability to distinguish between treatment responders and failures across different treatment groups.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!